Mirabegron for Overactive Bladder Treatment

Efficacy and Guidelines

• Mirabegron has been extensively studied in multiple high-quality randomized controlled trials, while flavoxate has limited evidence supporting its efficacy in current guidelines, as noted by the European Urology guidelines 1, 2, 3
• The European Association of Urology (EAU) guidelines include mirabegron as an effective treatment option for overactive bladder symptoms, with a strong evidence base 1, 2, 3

Treatment Recommendations

• First-line therapy should include behavioral interventions, and for pharmacological treatment, mirabegron 25-50 mg is recommended as an effective option with fewer anticholinergic side effects, according to Praxis Medical Insights 4
• Combination therapy with mirabegron plus an antimuscarinic agent like solifenacin may provide additional efficacy benefits for patients with inadequate response to monotherapy, as suggested by The Journal of Urology 5

Special Populations

• Mirabegron 25 mg has demonstrated safety and therapeutic efficacy in older patients with overactive bladder and multiple comorbidities, as reported in European Urology 1, 3